Development of glycoprotein-biomrkers for biliary tract cancers and establishment of novel diagnostic system using the combination of these biomarkers

2014 Fiscal Year Final Research Report

• Project/Area Number: 24390323
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Tokyo Women's Medical University
• Principal Investigator: YAMAMOTO Masakazu 東京女子医科大学, 医学部, 教授 (60220498)
• Co-Investigator(Kenkyū-buntansha): NAKAYAMA Masamiti 東京女子医科大学, 医学部, 講師 (00338980) ; ARIIZUMI Syunichi 東京女子医科大学, 医学部, 講師 (40277158) ; UTSUNOMIYA Hirohuto 和歌山県立医科大学, 中央機器施設, 准教授 (60264876) ; SHODA Junichi 筑波大学, 医学医療系, 教授 (90241827)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 胆道癌 / 糖鎖構造解析 / レクチン / 糖蛋白質 / バイオマーカー

Outline of Final Research Achievements

We have found a biliary tract cancer-specific glycoprotein biomarker, that is named WFA-positive sialyl-MUC1 (WFA-MUC1), and established a high sensitive assay system. In this study, we measured the levels of WFA-MUC1 in the serum from biliary tract cancers and intrahepatic cholangiocarcinoima under the project of multicenter-based clinical trial, and discuss the clinical significance of this biomarker. The serum concentraions of WFA-MUC1 were significantly higher in the cases of biliary tract cancers and intrahepatic cholangiocarcinoma than in those of benign biliary tract diseases and controls. The serum levels were not different in terms of the tumor stage and histology. The ROC analysis revealed that the capability of WFA-MUC1 to distinguish biliary tract cancers from benign diseases was superior to those of CA19-9 and CEA. Determination of WFA-MUC1 in the serum may be useful for the clinical practice of biliary tract cancers and intrahepatic cholangiocarcinoima.

Free Research Field

消化器外科学